Table 2.
Univariate and multivariate analyses of factors associated with OS.
| Factors | No. of Patients | Univariate (P) | Hazard Ratio (95% CI) |
Multivariate (P) |
|---|---|---|---|---|
| Age (years) <65 ≥65 |
515 399 |
0.027 |
1.245 (1.061–1.462) |
0.007 |
| Gender | 0.120 | |||
| Male | 538 | |||
| Female | 376 | |||
| Tumor size (cm) | 0.000 | 0.000 | ||
| ≤2 | 140 | |||
| >2 and ≤4 | 603 | 0.410 (1.089–1.828) | ||
| >4 | 171 | 1.989 (1.482–2.668) | ||
| RM | 0.000 | 0.001 | ||
| Negative | 656 | |||
| Positive | 258 | 1.352 (1.138–1.606) | ||
| Lymph node metastasis |
0.000 | 0.000 | ||
| Absent | 351 | |||
| Present | 563 | 1.667 (1.399–1.987) | ||
| Differentiation | 0.000 | 0.000 | ||
| Well D | 104 | |||
| Moderate D | 675 | 1.901 (1.414–2.556) | ||
| Poor D | 107 | 3.098 (2.175–4.413) | ||
| CA 19-9 Normal Elevated |
306 608 |
0.002 | 0.287 | |
| mGPS 0 1 and 2 |
739 175 |
0.001 |
1.268 (1.047–1.537) |
0.015 |
| NLR <3 ≥3 |
732 182 |
0.215 | ||
| PLR | 0.149 | |||
| <150 | 567 | |||
| ≥150 | 347 | |||
| Neoadjuvant treatment No Yes |
853 61 |
0.814 | ||
| Adjuvant treatment No Yes |
311 603 |
0.655 |
CA, carbohydrate antigen; CI, confidence interval; mGPS, modified Glasgow Prognostic Score; NLR, neutrophil-lymphocyte ratio; OS, overall survival; PLR, platelet-lymphocyte ratio.